Cargando…
Levetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Inducing Critical Molecular Changes in the Striatum
L-DOPA-induced dyskinesias (LID) remain a major problem of long-term therapy of Parkinson's disease. Levetiracetam, a new antiepileptic drug, has been shown to reduce LID, but the mechanisms underlying its effects are unknown. In this study, we assessed the effect of levetiracetam on key mediat...
Autores principales: | Du, Huan, Nie, Shuke, Chen, Guiqin, Ma, Kai, Xu, Yan, Zhang, Zhentao, Papa, Stella M., Cao, Xuebing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322303/ https://www.ncbi.nlm.nih.gov/pubmed/25692070 http://dx.doi.org/10.1155/2015/253878 |
Ejemplares similares
-
Antidyskinetic Effects of MEK Inhibitor Are Associated with Multiple Neurochemical Alterations in the Striatum of Hemiparkinsonian Rats
por: Chen, Guiqin, et al.
Publicado: (2017) -
Serotonergic system modulation holds promise for L-DOPA-induced dyskinesias in hemiparkinsonian rats: A systematic review
por: Farajdokht, Fereshteh, et al.
Publicado: (2020) -
Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model
por: dos Santos Pereira, Maurício, et al.
Publicado: (2022) -
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum
por: Porras, Gregory, et al.
Publicado: (2014) -
Nitric Oxide Synthase Inhibitor Improves De Novo and Long-Term l-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats
por: Padovan-Neto, Fernando Eduardo, et al.
Publicado: (2011)